TY - JOUR
T1 - Rat hepatocyte culture model of macrosteatosis
T2 - Effect of macrosteatosis induction and reversal on viability and liver-specific function
AU - Nativ, Nir I.
AU - Yarmush, Gabriel
AU - Chen, Alvin
AU - Dong, David
AU - Henry, Scot D.
AU - Guarrera, James V.
AU - Klein, Kenneth M.
AU - Maguire, Tim
AU - Schloss, Rene
AU - Berthiaume, Francois
AU - Yarmush, Martin L.
N1 - Funding Information:
The underlying research reported in the study was funded by the NIH Institutes of Health.
Funding Information:
This work was partially supported by NIH grants UH2 NS080733 and R01DK059766. Nir I. Nativ and Gabriel Yarmush were supported by an NIH-funded Biotechnology Training Fellowship.
PY - 2013/12
Y1 - 2013/12
N2 - Background & Aims A common cause of liver donor ineligibility is macrosteatosis. Recovery of such livers could enhance donor availability. Living donor studies have shown diet-induced reduction of macrosteatosis enables transplantation. However, cadaveric liver macrosteatotic reduction must be performed ex vivo within hours. Towards this goal, we investigated the effect of accelerated macrosteatosis reduction on hepatocyte viability and function using a novel system of macrosteatotic hepatocytes. Methods Hepatocytes isolated from lean Zucker rats were cultured in a collagen sandwich, incubated for 6 days in fatty acid-supplemented medium to induce steatosis, and then switched for 2 days to medium supplemented with lipid metabolism promoting agents. Intracellular lipid droplet size distribution and triglyceride, viability, albumin and urea secretion, and bile canalicular function were measured. Results Fatty acid-supplemented medium induced microsteatosis in 3 days and macrosteatosis in 6 days, the latter evidenced by large lipid droplets dislocating the nucleus to the cell periphery. Macrosteatosis significantly impaired all functions tested. Macrosteatosis decreased upon returning hepatocytes to standard medium, and the rate of decrease was 4-fold faster with supplemented agents, yielding 80% reduction in 2 days. Viability of macrosteatosis reduced hepatocytes was similar to control lean cells. Accelerated macrosteatotic reduction led to faster recovery of urea secretion and bile canalicular function, but not of albumin secretion. Conclusions Macrosteatosis reversibly decreases hepatocyte function and supplementary agents accelerate macrosteatosis reduction and some functional restoration with no effect on viability. This in vitro model may be useful to screen agents for macrosteatotic reduction in livers before transplantation.
AB - Background & Aims A common cause of liver donor ineligibility is macrosteatosis. Recovery of such livers could enhance donor availability. Living donor studies have shown diet-induced reduction of macrosteatosis enables transplantation. However, cadaveric liver macrosteatotic reduction must be performed ex vivo within hours. Towards this goal, we investigated the effect of accelerated macrosteatosis reduction on hepatocyte viability and function using a novel system of macrosteatotic hepatocytes. Methods Hepatocytes isolated from lean Zucker rats were cultured in a collagen sandwich, incubated for 6 days in fatty acid-supplemented medium to induce steatosis, and then switched for 2 days to medium supplemented with lipid metabolism promoting agents. Intracellular lipid droplet size distribution and triglyceride, viability, albumin and urea secretion, and bile canalicular function were measured. Results Fatty acid-supplemented medium induced microsteatosis in 3 days and macrosteatosis in 6 days, the latter evidenced by large lipid droplets dislocating the nucleus to the cell periphery. Macrosteatosis significantly impaired all functions tested. Macrosteatosis decreased upon returning hepatocytes to standard medium, and the rate of decrease was 4-fold faster with supplemented agents, yielding 80% reduction in 2 days. Viability of macrosteatosis reduced hepatocytes was similar to control lean cells. Accelerated macrosteatotic reduction led to faster recovery of urea secretion and bile canalicular function, but not of albumin secretion. Conclusions Macrosteatosis reversibly decreases hepatocyte function and supplementary agents accelerate macrosteatosis reduction and some functional restoration with no effect on viability. This in vitro model may be useful to screen agents for macrosteatotic reduction in livers before transplantation.
KW - Albumin
KW - Bile
KW - Lipid metabolism
KW - Liver transplantation
KW - Steatosis
KW - Triglyceride
KW - Urea
UR - http://www.scopus.com/inward/record.url?scp=84888012679&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888012679&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2013.07.019
DO - 10.1016/j.jhep.2013.07.019
M3 - Article
C2 - 23872604
AN - SCOPUS:84888012679
SN - 0168-8278
VL - 59
SP - 1307
EP - 1314
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 6
ER -